Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 14/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370191 | 0.90 | MAOA (0.63) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL12956122 | 0.89 | MAOA (0.56) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL3326714 | 0.88 | MAOA (0.70) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL4488687 | 0.87 | MAOA (0.57) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL1035538 | 0.87 | MAOA (0.57) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL16766787 | 0.87 | MAOA (0.57) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL4493776 | 0.86 | MAOA (0.54) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL16737257 | 0.86 | MAOA (0.65) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL4487322 | 0.86 | MAOA (0.56) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL4489019 | 0.86 | MAOA (0.65) | MAOAKCNH2MAOBCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498350-B2 | Oxazolidinones as antibacterial agents | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-7498350-B2 | Oxazolidinones as antibacterial agents | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-7498350-B2 | Oxazolidinones as antibacterial agents | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20060116386-A1 | Oxazolidinones as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116386-A1 | Oxazolidinones as antibacterial agents | MRPL21, MRPS23, DPP3 | MAOA 279/4885KCNH2 1224/4885MAOB 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.